Generation Bio Co. (NASDAQ:GBIO) Insider Douglas Kerr Sells 11,267 Shares of Stock


Share on StockTwits

Generation Bio Co. (NASDAQ:GBIO) insider Douglas Kerr sold 11,267 shares of the company’s stock in a transaction dated Monday, January 11th. The stock was sold at an average price of $27.58, for a total value of $310,743.86. Following the completion of the sale, the insider now owns 337,825 shares of the company’s stock, valued at approximately $9,317,213.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Generation Bio stock opened at $28.90 on Thursday. The stock has a 50 day moving average of $35.62 and a 200 day moving average of $27.95. Generation Bio Co. has a 12 month low of $17.00 and a 12 month high of $55.72.

Generation Bio (NASDAQ:GBIO) last announced its quarterly earnings results on Sunday, November 15th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.01). Research analysts predict that Generation Bio Co. will post -2.89 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. Strs Ohio bought a new stake in shares of Generation Bio in the 3rd quarter valued at approximately $95,000. California State Teachers Retirement System bought a new stake in shares of Generation Bio in the 3rd quarter valued at approximately $574,000. Morgan Stanley purchased a new stake in shares of Generation Bio in the third quarter worth approximately $59,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Generation Bio in the third quarter worth approximately $2,497,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Generation Bio by 12.8% in the third quarter. JPMorgan Chase & Co. now owns 526,634 shares of the company’s stock worth $16,284,000 after buying an additional 59,684 shares during the period. 58.52% of the stock is owned by institutional investors and hedge funds.

Several analysts recently issued reports on the company. Zacks Investment Research upgraded Generation Bio from a “sell” rating to a “hold” rating in a research report on Tuesday, October 13th. BidaskClub cut Generation Bio from a “buy” rating to a “hold” rating in a research report on Thursday, December 31st. Finally, ValuEngine upgraded Generation Bio from a “hold” rating to a “buy” rating in a research report on Monday, October 19th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $32.33.

Generation Bio Company Profile

Generation Bio Co, a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.

Featured Story: What is the balance sheet?

Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.